Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Double-Blind, Randomized, Cross-Over Trial of Aged Garlic Extract for Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03211767
Recruitment Status : Completed
First Posted : July 7, 2017
Last Update Posted : February 12, 2019
Sponsor:
Collaborators:
Wakunga of America Co. Ltd.
Purity Life Health Products LP
Information provided by (Responsible Party):
University of Manitoba

Brief Summary:

The primary objective of this trial is to assess the effect of consumption of aged garlic extract powder on 24 h systolic and diastolic ambulatory blood pressure in hypertensive individuals following 8 weeks of supplementation.

Additional secondary objectives are to assess the effects of aged garlic extract powder intake for 8 weeks on lipid profile (TC, HDL-C, LDL-C, and TG concentrations), blood glucose, office blood pressure, pulse-wave velocity and augmentation index, body mass index, and waist and hip circumference.


Condition or disease Intervention/treatment Phase
Hypertension Dietary Supplement: Aged garlic extract Dietary Supplement: Placebo Not Applicable

Detailed Description:

Forty hypertensive volunteers between 18 and 75 years will be recruited from the Winnipeg (Manitoba, Canada) area to participate in a two arm crossover, double-blind, randomized, placebo-controlled intervention study for 8 weeks per study period following obtainment of informed consent.

The 2 periods of treatment will include:

  1. Treatment period: One capsule twice a day, providing 600 mg each of aged garlic extract powder, for a total of 1200 mg/day of aged garlic extract powder.
  2. Control period: The control product will be an identical-looking placebo capsules containing cellulose, which is being used as a filler in the treatment capsules.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-Blind, Randomized, Cross-Over Trial of Aged Garlic Extract for Hypertension
Actual Study Start Date : October 12, 2017
Actual Primary Completion Date : July 25, 2018
Actual Study Completion Date : July 25, 2018


Arm Intervention/treatment
Active Comparator: Aged garlic extract
2 capsules per day containing aged garlic extract
Dietary Supplement: Aged garlic extract
Each capsule contains 600mg of aged garlic extract powder

Placebo Comparator: Placebo
2 capsules per day without aged garlic extract
Dietary Supplement: Placebo
Each capsule contains cellulose as a filler.




Primary Outcome Measures :
  1. 24 hour ambulatory blood pressure [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Blood total cholesterol [ Time Frame: 8 weeks ]
  2. Blood low-density lipoprotein cholesterol [ Time Frame: 8 weeks ]
  3. Blood high-density lipoprotein cholesterol [ Time Frame: 8 weeks ]
  4. Blood triglycerides [ Time Frame: 8 weeks ]
  5. Office blood pressure [ Time Frame: 8 weeks ]
  6. Pulse wave velocity [ Time Frame: 8 weeks ]
    Measured by Mobil-O-Graph

  7. Augmentation index [ Time Frame: 8 weeks ]
    Measured by Mobil-O-Graph

  8. Body mass index [ Time Frame: 8 weeks ]
  9. Waist circumference [ Time Frame: 8 weeks ]
  10. Hip circumference [ Time Frame: 8 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to give written informed consent.
  • Age: greater than or equal to 40 and less than or equal to 70 years.
  • Systolic blood pressure140-160mmHg and/or diastolic blood pressure 90-100 mmHg
  • LDL-C less than or equal to 4.9mmol/L
  • Those on a stable dose of blood pressure lowering or lipid-lowering medication for greater than or equal to 3 months; if a participant chooses to stop taking blood pressure lowering medications, they will be required to have a minimum 3 month washout period prior to commencement of the study; all other medications medications will be permitted if they are on a stable dose before the start of the study
  • Gender: Male and women who are not pregnant (determined by a negative urine pregnancy test at screening for women of childbearing potential) or lactating.
  • Language: Participants must be able to read, write and speak English.

Exclusion Criteria:

  • Systolic blood pressure > 160mmHg and/or diastolic blood pressure >100mmHg
  • Those currently taking (or have taken within the last 3 months) lipid-lowering or blood pressure-lowering supplements (i.e., omega-3 supplements, plant sterols/stanols foods and/or supplements, fibre, etc.)
  • Patients with unstable or serious illness, for example, dementia, terminal illness, recent bereavement, secondary hypertension, recent significant medical diagnosis.
  • History of cancer, chronic illness, cardiovascular problems, liver and kidney disease (including chronic kidney disease (GFR < 60ml/min/1.732)), diabetes, inflammatory bowel disease, pancreatitis, gallbladder or biliary disease, neurological/psychological disease, bleeding disorders, experienced platelet abnormalities, macrovascular target organ damage (including cerebrovascular disease, stroke, hypertensive retinopathy, left ventricular dysfunction, angina pectoris, myocardial infarction, and peripheral artery disease)
  • History of taking any type of garlic preparation (i.e., dried garlic homogenate, aged garlic extract, processed garlic capsule, time-released garlic powder tablet, regular garlic pill, garlic powder and garlic oil) in the past 6 months. in the past 3 months. (Note: regular garlic clove consumption as part of prepared meals, cooking preparations, etc. are permitted throughout the study period)
  • Plan to consume any type of garlic preparation (i.e., dried garlic homogenate, aged garlic extract, processed garlic capsule, time-released garlic powder tablet, regular garlic pill, garlic powder and garlic oil. at any time during the study. (Note: regular garlic clove consumption as part of prepared meals, cooking preparations, etc. are permitted throughout the study period)
  • Have gained or lost greater than or equal to 10lbs in the previous 3 months, or plan to lose weight at any time during the study
  • Plan to become pregnant during the study period.
  • Women of childbearing potential not using effective contraception which include: Hormonal contraceptives including combined oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormonal implants; Intrauterine devices (IUD) or Intrauterine system (IUS); Tubal ligation; Vasectomy of partner; Double barrier method (use of physical barrier by both partners, e.g. male condom and diaphragm, male condom and cervical cap)
  • Consumption of more than 2 alcoholic drinks/day, or > 14 alcoholic beverages a week, or history of alcoholism or drug dependence.
  • History of allergy to garlic, microcrystalline cellulose, silicon dioxide, magnesium stearate, gelatin, hydroxypropylcellulose, or caramel coloring
  • Any planned surgeries any time during the study
  • Taking medications with psychotropic properties for less than 3 months, i.e., those taking medications with psychotropic properties, such as anti-depressants, anti-anxiety, etc., at a stable consistent dose for a minimum of 3 months are eligible for the study, as long as the medication is consumed at a stable, consistent dose throughout the study period
  • Smokers
  • Exercising > 15 miles/wk or 4,000 kcal/wk

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03211767


Locations
Layout table for location information
Canada, Manitoba
Richardson Centre for Functional Foods and Nutraceuticals
Winnipeg, Manitoba, Canada, R3T 6C5
Sponsors and Collaborators
University of Manitoba
Wakunga of America Co. Ltd.
Purity Life Health Products LP
Investigators
Layout table for investigator information
Principal Investigator: Peter Jones, PhD University of Manitoba
Layout table for additonal information
Responsible Party: University of Manitoba
ClinicalTrials.gov Identifier: NCT03211767    
Other Study ID Numbers: HS19581 (B2016:019)
First Posted: July 7, 2017    Key Record Dates
Last Update Posted: February 12, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases